Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05954442 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05954442 · ClinicalTrials.gov record · last posted 2024-01-16

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Study acronym: BCTOP-T-M03
StatusRecruiting
PhasePhase 3
Started2023-09-13
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 16, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic triple-negative breast cancer, luminal androgen receptor (LAR) subtype with PI3K/AKT/mTOR (PAM) pathway mutation, as the first-line treatment.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2023-07-13; most recent amendment 2024-01-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-10-24
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05954442
Lead Sponsor Fudan University
Conditions Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
Enrollment 203 participants
Start Date 2023-09-13
Primary Completion 2025-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2024-01-16